SIROWA VILNIUS - Company finances
|
EUR
|
2018
From: 2018-01-01
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | 22,582,170 | 23,892,227 | 19,859,019 | 23,316,472 | 32,542,385 | 35,142,215 | 30,440,317 | 32,653,703 |
| Profit before tax | 517,668 | 383,060 | 490,974 | 1,054,767 | 1,980,354 | 1,632,286 | 784,399 | 550,264 |
| Net profit | 423,962 | 302,008 | 390,531 | 876,369 | 1,655,670 | 1,356,632 | 615,443 | 409,523 |
| Equity | 2,522,531 | 2,594,539 | 2,757,070 | 3,633,439 | 4,989,109 | 5,945,741 | 6,061,184 | 5,552,830 |
| Liabilities | 8,860,731 | 9,422,041 | 8,865,202 | 7,518,540 | 11,433,445 | 12,734,796 | 12,174,640 | 14,350,098 |
| Non-current assets | 110,569 | 115,728 | 106,627 | 110,346 | 88,235 | 671,461 | 446,920 | 446,590 |
| Current assets | 11,295,726 | 11,982,315 | 11,700,869 | 11,276,444 | 16,519,494 | 18,189,713 | 17,935,020 | 19,679,063 |
| Total assets | 11,406,295 | 12,098,043 | 11,807,496 | 11,386,790 | 16,607,729 | 18,861,174 | 18,381,940 | 20,125,653 |
|
Taxes paid
|
||||||||
| STI taxes | - | - | - | - | - | 3,964,266 | 3,186,721 | 3,074,888 |
| Social insurance contributions | - | - | - | - | - | 536,045 | 591,923 | 612,614 |
|
Financial indicators
|
||||||||
| Revenue change y/y | +7.7% | +5.8% | -16.9% | +17.4% | +39.6% | +8.0% | -13.4% | +7.3% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 3.7% | 2.5% | 3.3% | 7.7% | 10.0% | 7.2% | 3.3% | 2.0% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 16.8% | 11.6% | 14.2% | 24.1% | 33.2% | 22.8% | 10.2% | 7.4% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 1.9% | 1.3% | 2.0% | 3.8% | 5.1% | 3.9% | 2.0% | 1.3% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | 2.3% | 1.6% | 2.5% | 4.5% | 6.1% | 4.6% | 2.6% | 1.7% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 3.5 | 3.6 | 3.2 | 2.1 | 2.3 | 2.1 | 2.0 | 2.6 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 344,766 | 350,497 | 311,922 | 397,440 | 535,677 | 548,383 | 458,899 | 483,759 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
SIROWA VILNIUS - Social security debts
The company had no debts to Sodra
SIROWA VILNIUS - VMI tax arrears
| From | To | Overdue, € |
|---|---|---|
| 2025-02-21 | 2025-02-21 | 0.12 |
| 2025-02-20 | 2025-02-20 | 145.0 |
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
SIROWA VILNIUS, UAB (code 111686053) is a Private Limited Liability Company operating in the wholesale of pharmaceutical and medical goods. In 2025, revenue increased to €32.65M, up 7.3% year on year, after €30.44M in 2024 and €35.14M in 2023, indicating a partial recovery from the 2024 decline but still below the 2023 level. Net profit continued to ease, falling from €1.36M in 2023 to €615.4K in 2024 and €409.5K in 2025, with the profit margin at 1.3% in 2025. The balance sheet remained substantial, with total assets of €20.13M, equity of €5.55M and liabilities of €14.35M at year-end 2025. Key ratios point to moderate leverage and solid sales intensity: equity ratio 27.6%, debt-to-equity 2.58, asset turnover 1.62x, ROE 7.4% and ROA 2.0%. Revenue per employee reached €487.4K, while profit per employee was €6.1K, showing strong productivity but limited conversion of turnover into profit.